IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC 50 of 42 nM and 109 nM, for MST1 and MST2. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 ameliorates diabetes in Streptozotocin -induced type 1 diabetes (T1D) mouse models.